21-11-2023

Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.

14-11-2023

Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023

20-10-2023

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG

17-10-2023, 16:57 CEST (Ad hoc press release)

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.

28-09-2023

Eckert & Ziegler Receives Award for Professional Training

13-09-2023

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

21-07-2023, 15:21 CEST (Ad hoc press release)

Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.

07-06-2023

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.

15-05-2023

​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler

08-05-2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

20-04-2023

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

04-04-2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

24-03-2023

​​​​​​​Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)

03-03-2023

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

17-01-2023, 12:47 CET (Ad hoc press release)

Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures